Codon-Optimized rAAV Vectors for Retinal Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Choroideremia and achromatopsia are retinal degeneration diseases that lead to significant vision loss due to defects in Rab Escort Protein-1 (REP-1) and cyclic nucleotide-gated channel subunits, for which current treatments lack effective gene therapy solutions.
Innovation Solution
Development of codon-optimized cDNA sequences for REP-1, CNGA3, and CNGB3 encoded in recombinant adeno-associated virus (rAAV) vectors, optimized for expression in human cells, using AAV capsids and inverted terminal repeat sequences to direct protein expression in host cells, facilitating gene augmentation therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gene therapy is developed for choroideremia and achromatopsia, then treatment effectiveness is improved, but development complexity and cost increase
Solution Approach 1:
The gene therapy approach is segmented into multiple components: codon-optimized cDNA sequences for REP-1, CNGA3, and CNGB3 are developed separately, then packaged into recombinant adeno-associated virus (rAAV) vectors. This segmentation allows each gene target to be optimized and tested independently before combination therapy, reducing overall development complexity while maintaining treatment effectiveness.
2Productivity
If codon-optimized cDNA sequences are used in rAAV vectors, then protein expression levels increase, but vector design and manufacturing complexity increase
Solution Approach 1:
Codon optimization changes the nucleotide sequence parameters of the cDNA without altering the amino acid sequence. This parameter change optimizes translation efficiency and protein expression levels. The optimized sequences are then integrated into standardized rAAV vector backbones, which streamlines manufacturing by separating the optimization step from the vector production process.
Solution Approach 2:
Codon optimization is performed as a preliminary action before vector construction and manufacturing. By pre-optimizing the cDNA sequences for maximum expression efficiency, the subsequent vector manufacturing process becomes more straightforward, as the sequences are already prepared for optimal performance without requiring complex manufacturing adjustments.
3Reliability
If gene augmentation therapy is implemented, then disease progression is halted or slowed, but treatment cost and accessibility challenges arise
Solution Approach 1:
The rAAV vector system serves multiple functions: it can deliver different codon-optimized cDNA sequences for various gene targets (REP-1, CNGA3, CNGB3), accommodate different promoter elements for tissue-specific expression, and utilize standardized manufacturing platforms. This universality allows a single therapeutic approach to address multiple genetic causes of retinal degeneration, potentially reducing overall treatment costs and improving accessibility through platform technology.
Data Source
AI summary
Compositions and methods are provided for treating ocular disorders in a subject are provided. In one aspect, an adeno-associated viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding CNGA3. In another aspect, an adeno-associated viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding CNGB3. In another aspect, an adeno-associated viral vector is provided which includes a nucleic acid molecule comprising a sequence encoding REP-1. In desired embodiments, the subject is human, cat, dog, sheep, or non-human primate.